香雪製藥(300147.SZ):控股股東及其關聯方佔用公司資金 佔用餘額約5.31億元
格隆匯 4 月 6日丨香雪製藥(300147.SZ)公佈,公司在自查中發現存在控股股東及其關聯方佔用上市公司資金的情形,截至公吿披露日資金佔用餘額合計53094.04萬元,佔公司最近一期經審計淨資產的15.22%。
公司將進一步梳理資金佔用的詳細情況,後續將就事項進展及具體情況持續進行信息披露;
公司已召開第八屆董事會第三十次會議審議通過了《關於收購廣州協和精準醫療有限公司100%股權暨關聯交易補充事項的議案》,董事會同意公司有權在應向廣州市崑崙投資有限公司(“崑崙投資”)支付的購買廣州協和精準醫療有限公司100%股權轉讓價款中優先扣減和抵銷崑崙投資應償還佔用資金的任何金額,股權轉讓價款中被如此扣減和抵銷的任何部分均視為已由公司支付,以資抵債儘快解決非經營性資金佔用,以消除對公司的不利影響,並同意將該事項提交公司股東大會審議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.